MedPath

A comparative study between hyperbaric ropivacaine and isobaric ropivacaine foe spinal anesthesia

Phase 4
Completed
Conditions
Medical and Surgical,
Registration Number
CTRI/2023/11/060226
Lead Sponsor
Dr Sunil Chiruvella
Brief Summary

Various local anesthetics commonly used for spinal anesthesia . Nowadays Ropivacaine is gaining increasing popularity because of reduced risk of central nervous system and cardiac toxicity , early ambulation and discharge with good quality of postoperative analgesia .Hyperbaric ropivacaine produces more reliable sensory and motor blockade with faster onset, better quality of muscle relaxation than isobaric ropivacaine . The aim of the study is  to compare the efficacy of hyperbaric and isobaric ropivacaine in patients undergoing hip surgeries.  A randomised double blind study will be conducted in 60 patients of either sex undergoing hip surgeries will be divided into two groups A (30) and B (30) who will receive 15mg of 0.5% hyperbaric ropivacaine and 15mg of 0.5% isobaric ropivacaine respectively.

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
60
Inclusion Criteria

Not provided

Exclusion Criteria

Patient refusal Allergic to local anaesthetics Pregnancy Absolute contraindications for Regional anesthesia.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Primary objective is to compare onset and duration of sensory and motor blockade5 mins | 10 mins | 15 mins | 30 mins | 1 hour | 2 hours | 6 hours | 12 hours
Secondary Outcome Measures
NameTimeMethod
Secondary objective is to compare hemodynamic changes, intraoperative analgesia requirement and adverse effects in both groups5 mins

Trial Locations

Locations (1)

Government General Hospital

🇮🇳

Cuddapah, ANDHRA PRADESH, India

Government General Hospital
🇮🇳Cuddapah, ANDHRA PRADESH, India
Dr SUNKESULA SONIA BEGUM
Principal investigator
8897573489
sonia.sunkesula@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.